<DOC>
	<DOCNO>NCT00003463</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase I trial study effectiveness carmustine wafer plus irinotecan treating patient recurrent supratentorial high grade glioma .</brief_summary>
	<brief_title>Carmustine Wafers Plus Irinotecan Treating Patients With Recurrent Supratentorial High Grade Gliomas</brief_title>
	<detailed_description>OBJECTIVES : - Define maximum tolerate dose irinotecan give combination Gliadel wafer ( carmustine ) patient recurrent glioblastoma multiforme , anaplastic astrocytoma , gliosarcoma . - Define toxicity irinotecan give combination Gliadel wafers patient . OUTLINE : This dose escalation study . All patient undergo surgical resection . At time surgery , eight Gliadel wafer ( contain carmustine ) implant resected tumor cavity . Cohorts 3 patient receive escalate dos irinotecan IV 90 minute weekly within 3 week Gliadel wafer implantation . One course treatment consist 4 week irinotecan 2 week rest . If 1 patient experience dose limit toxicity ( DLT ) dose level , additional 3 patient enter dose level . If 2 patient experience DLT , maximum tolerate dose ( MTD ) surpass total 6 patient treat previous dose level . The MTD define high dose 1 6 patient experience DLT . Treatment continue 12 course absence unacceptable toxicity disease progression . Patients follow least 4 month . PROJECTED ACCRUAL : Approximately 18 patient accrue study 9 month .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm recurrent supratentorial glioblastoma multiforme , anaplastic astrocytoma , gliosarcoma Must able undergo surgical resection At least 1 bidimensionally measurable lesion document GdMRI within 72 hour surgical implantation Gliadel wafers Not require immediate radiotherapy PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 70100 % Life expectancy : Greater 12 week Hematopoietic : Absolute neutrophil count least 1,500/mm^3 Platelet count least 125,000/mm^3 Hematocrit least 29 % Hepatic : Bilirubin le 1.5 time upper limit normal ( ULN ) SGOT SGPT less 2.5 time ULN Alkaline phosphatase less 2 time ULN Renal : BUN le 1.5 time ULN Creatinine less 1.5 time ULN Neurological : Must neurologically stable Other : HIV negative No AIDSrelated illness No nonmalignant systemic disease would make patient poor medical risk No acute infection require intravenous antibiotic Not pregnant nursing Negative pregnancy test 24 hour prior study Effective contraception require fertile patient PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior irinotecan At least 6 week since chemotherapy unless unequivocal evidence tumor progression chemotherapy Endocrine therapy : At least 1 week nonincreasing dose steroid prior study Radiotherapy : At least 6 week since radiotherapy unless unequivocal evidence tumor progression radiotherapy No concurrent radiotherapy Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>recurrent adult brain tumor</keyword>
	<keyword>adult brain stem glioma</keyword>
	<keyword>adult glioblastoma</keyword>
	<keyword>adult anaplastic astrocytoma</keyword>
	<keyword>adult mixed glioma</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
</DOC>